Successfully partial exited Digiwin Software, a portfolio company of CID Fund II

Jan 20, 2017

Invested in 2007, assisted its privatization from Taiwan stock exchange and expansion in mainland China. The CID Group (“CID”) is pleased to announce the successful block trade of its partial exit of Digiwin Software Co.,LTD. (“Digiwin” or “the Company”, Stock Code: 300378.CH), a portfolio company of CID Greater China Fund II (“Fund II”), on January 20th, 2017.

Read more X

JMC Electronics, one of CID Fund IV’s portfolio companies, has successfully transferred to the Main Board from the Emerging Board

Jan 10, 2017

Established in 1973, JMC is a leading provider of semiconductor flexible organic substrate for LCD driver (also known as Tape Chip-on-Film) in Taiwan. With its R&D commitment in latest Subtractive and Semi-Additive technologies, JMC has the competitive edge in penetrating into different market sectors, such as high-end wearable devices, in addition to its strength in large-size panel market. JMC also seized the driver IC supply chain partnership in China, such as BOE and Huawei.

Read more X

Crown Bioscience, one of CID Fund III portfolios, was sucessfully transferred from Emerging Board of Taipei Exchange to the Main Board

Dec 12, 2016

Headquartered in Silicon Valley with research facilities in the United States, United Kingdom, mainland China and Taiwan, the Company provides cutting-edge translational platforms helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. With the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models, the company can help the biopharmaceutical clients accelerate their new drug development programs significantly.

Read more X